Eli Lilly projects 32% revenue growth for 2025, fueled by incretin expansion and new launches

Earnings Call Insights: Eli Lilly and Company (NYSE:LLY) Q4 2024

Management View

  • CEO David Ricks highlighted a 45% revenue growth in Q4, with significant contributions from Mounjaro and Zepbound. He emphasized ongoing expansion in manufacturing to meet demand and investments of over $23 billion

Leave a Reply

Your email address will not be published. Required fields are marked *